CDMO Flamma Group is to invest about $200 million over the next three years across its network of sites in Italy, the US and China, as it “continues to respond to market demands that require future growth and opportunity”. This includes:

* Revamping the site at Bulciago, Italy, that was acquired in 2022

* Completing the new GMP facility at the Flamma Honkai site in Dalian, China, where small molecule API and NCE capacity will ultimately quadruple to 800 m³ to meet growing domestic demand